Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis - anthrax spores(5m/ml) - parenteral liquid/solution/suspension - vaccine - cattle | pigs | sheep | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ew - bacillus anthracis | anthrax

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - bacillus anthracis (sterne 34f2 strain) - parenteral liquid/solution/suspension - bacillus anthracis (sterne 34f2 strain) vaccine-microbial active 0.0 ml - immunotherapy - cattle | pigs | sheep | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ew - bacillus anthracis | anthrax

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

csl limited - anthrax spore - immunotherapy - cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | heifer | h - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus

New Zealand - English - Ministry for Primary Industries

ministry for primary industries - bacillus anthracis (sterne 34f2 strain) live spores - bacillus anthracis (sterne 34f2 strain) live spores 0 vaccine - vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fort dodge australia pty limited - anthrax spore - immunotherapy - cattle | goat | horse | pigs | sheep | beef | billy | boar | bos indicus | bos taurus | bovine | buck | buffalo | bull | bullock - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus

United States - English - NLM (National Library of Medicine)

emergent biosolutions canada inc. - anthrax immune globulin human (unii: vkz83s945z) (anthrax immune globulin human - unii:vkz83s945z) - anthrax immune globulin human 60 [iu] in 35 ml - anthrasil is an anthrax immune globulin intravenous (human) indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. the effectiveness of anthrasil is based solely on efficacy studies conducted in animal models of inhalational anthrax [see 13.2 animal toxicology and/or pharmacology]. limitations: risk summary there are no human data to establish the presence or absence of anthrasil associated risk. risk summary there are no data to assess the presence or absence of anthrasil in human milk, the effects on the breastfed child or the effects on milk production/excretion. safety and effectiveness of anthrasil in the pediatric population (≤16 yrs of age) have not been studied. allometric scaling was used to derive dosing regimens to provide pediatric patients with exposure comparable to the observed exposure in adults receiving 420 units and 840 units. the dose for pediatric patients is based on body weight. safety and effectiveness of

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alum precipitated sterile filtrate) suspension for injection 0.5ml ampoules (secretary of state for health - anthrax antigens - suspension for injection

Canada - English - Health Canada

emergent biosolutions canada inc - anthrax immunoglobulin (human) - solution - 60unit - anthrax immunoglobulin (human) 60unit - serums

Canada - English - Health Canada

emergent biodefense operations lansing llc - anthrax antigen filtrate - suspension - 50mcg - anthrax antigen filtrate 50mcg - vaccines

Singapore - English - HSA (Health Sciences Authority)

emergent sales and marketing singapore pte. ltd. - anthrax antigen protein - injection, suspension - 50μg/dose (nominal) - anthrax antigen protein 50μg/dose (nominal)